Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessia Di Sapio

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Journal of Neurology|December 15, 2010
One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patientsSimona Malucchi, Francesca Gilli, Marzia Caldano, et al.
Journal of Neurology|September 23, 2024
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical settingSimona Malucchi, Cecilia Irene Bava, Paola Valentino, et al.
Neurology and Therapy|December 5, 2016
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational StudySimona Malucchi, Marco Capobianco, Marianna Lo Re, et al.
Frontiers in Neurology|April 14, 2025
Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practiceDiego Centonze, Alessia Di Sapio, Vincenzo Brescia Morra, et al.
Cephalalgia : an International Journal of Headache|April 25, 2015
The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practiceAntonio Bertolotto, Maria Malentacchi, Marco Capobianco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patientsMarco Capobianco, Annalisa Rizzo, Simona Malucchi, et al.
Brain, Behavior, and Immunity|May 26, 2026
Serum neurofilament light chain increases in healthy postpartum: is it subclinical brain damage or neuroplasticity?Antonio Bertolotto, Paola Valentino, Cecilia Irene Bava, et al.
Orphanet Journal of Rare Diseases|August 22, 2020
Screening for Fabry disease in unknown origin axonal polyneuropathy: to do or not to do, this is the question!Eugenia Rota, Marina Grandis, Alessia Di Sapio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 10, 2025
Social determinants of health in multiple sclerosis in Italy: A scoping reviewMarta Ponzano, Maurizio Mario Fedriga, Alessio Signori, et al.
Journal of Neuroimmunology|October 24, 2007
Anti-interferon-beta neutralising activity is not entirely mediated by antibodiesFrancesca Gilli, Fabiana Marnetto, Marzia Caldano, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Journal of Neurology|December 15, 2010
One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patientsSimona Malucchi, Francesca Gilli, Marzia Caldano, et al.
Journal of Neurology|September 23, 2024
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical settingSimona Malucchi, Cecilia Irene Bava, Paola Valentino, et al.
Neurology and Therapy|December 5, 2016
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational StudySimona Malucchi, Marco Capobianco, Marianna Lo Re, et al.
Frontiers in Neurology|April 14, 2025
Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practiceDiego Centonze, Alessia Di Sapio, Vincenzo Brescia Morra, et al.
Cephalalgia : an International Journal of Headache|April 25, 2015
The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practiceAntonio Bertolotto, Maria Malentacchi, Marco Capobianco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patientsMarco Capobianco, Annalisa Rizzo, Simona Malucchi, et al.
Brain, Behavior, and Immunity|May 26, 2026
Serum neurofilament light chain increases in healthy postpartum: is it subclinical brain damage or neuroplasticity?Antonio Bertolotto, Paola Valentino, Cecilia Irene Bava, et al.
Orphanet Journal of Rare Diseases|August 22, 2020
Screening for Fabry disease in unknown origin axonal polyneuropathy: to do or not to do, this is the question!Eugenia Rota, Marina Grandis, Alessia Di Sapio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 10, 2025
Social determinants of health in multiple sclerosis in Italy: A scoping reviewMarta Ponzano, Maurizio Mario Fedriga, Alessio Signori, et al.
Journal of Neuroimmunology|October 24, 2007
Anti-interferon-beta neutralising activity is not entirely mediated by antibodiesFrancesca Gilli, Fabiana Marnetto, Marzia Caldano, et al.
Pageof 6